Laddar...

Targeting PI3K, mTOR, ERK, and Bcl-2 signaling network shows superior antileukemic activity against AML ex vivo

Acute myeloid leukemia (AML) remains challenging to treat and needs more effective treatments. The PI3K/mTOR pathway is involved in cell survival and has been shown to be constitutively active in 50–80% of AML patients. However, targeting the PI3K/mTOR pathway results in activation of the ERK pathwa...

Full beskrivning

Sparad:

Bibliografiska uppgifter
I publikationen:	Biochem Pharmacol
Huvudupphovsmän:	Su, Yongwei, Li, Xinyu, Ma, Jun, Zhao, Jianyun, Liu, Shuang, Wang, Guan, Edwards, Holly, Taub, Jeffrey W., Lin, Hai, Ge, Yubin
Materialtyp:	Artigo
Språk:	Inglês
Publicerad:	2017
Ämnen:	Article
Länkar:	https://ncbi.nlm.nih.gov/pmc/articles/PMC6858997/ https://ncbi.nlm.nih.gov/pubmed/29208365 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bcp.2017.11.022
Taggar:	Lägg till en tagg Inga taggar, Lägg till första taggen!

Targeting PI3K, mTOR, ERK, and Bcl-2 signaling network shows superior antileukemic activity against AML ex vivo

Liknande verk